EMAS position statement: Fertility preservation.
BACKGROUND
The increasing incidence of malignant diseases that often require gonadotoxic treatment and the tendency to become a parent later in life result in an increased need for fertility preservation.


OBJECTIVE
The aim of this position statement is to provide and critically appraise evidence on available options for fertility preservation in both pre-pubertal and post-pubertal men and women.


METHODS
Literature review and consensus of expert opinion.


CONCLUSIONS
Fertility preservation should be a priority when treating children or adults of reproductive age with agents that may have hazardous effects on the reproductive system. Gonadotoxicity should be kept at a minimum. If gonadotoxic treatment has to be used, methods of fertility preservation should be discussed, as early as possible.
Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Greece.
Gesthimani
G
Mintziori
Second Department of Obstetrics and Gynecology, National and Capodestrian University of Athens, Greece.
Irene
I
Lambrinoudaki
Department of Obstetrics and Gynecology, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania; Department of Obstetrics and Gynecology, 'Dr. I. Cantacuzino' Hospital, Bucharest, Romania.
Iuliana
I
Ceausu
Breast Clinic and Menopause Clinic, University Hospital, De Pintelaan 185, 9000 Gent, Belgium.
Herman
H
Depypere
Department of Obstetrics and Gynecology, Istanbul University, Cerrahpasa School of Medicine, Valikonagi Cad. No. 93/4, Nisantasi 34365, Istanbul, Turkey.
C Tamer
CT
Erel
Department of Obstetrics and Gynecology, Zaragoza University Facultad de Medicina, Hospital Clínico, Zaragoza 50009, Spain.
Faustino R
FR
Pérez-López
Department of Medicine, Cardiology Unit and Head Centre for Gender Medicine, Karolinska Institutet and Karolinska University Hospital, Thorax N3:06, SE 17176 Stockholm, Sweden.
Karin
K
Schenck-Gustafsson
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Yvonne T
YT
van der Schouw
Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56100, Pisa, Italy.
Tommaso
T
Simoncini
Menopause and Metabolic Bone Disease Unit, Hôpital Paule de Viguier, F-31059 Toulouse cedex 09, France.
Florence
F
Tremollieres
Unit for Human Reproduction, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Greece.
Basil C
BC
Tarlatzis
Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK.
Margaret
M
Rees
Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Greece. Electronic address: dimitrios.goulis@otenet.gr.
Dimitrios G
DG
Goulis
D000328:Adult; D002648:Child; D032921:Consensus; D005260:Female; D005298:Fertility; D059247:Fertility Preservation / Q000379:methods; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000517:prevention & control*; D007248:Infertility, Male / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D012098:Reproduction / Q000187:drug effects / Q000528:radiation effects; D012955:Societies, Medical
Embryo cryopreservation; Fertility preservation; Gonadotoxicity; Oocyte cryopreservation; Sperm cryopreservation